Journal Article

Clinical, biochemical, and genetic spectrum of MADD in a South African cohort: an ICGNMD study

Schoonen, Maryke, Vorster, Barend C., Smuts, Izelle, Wanders, Ronald J. A., Dercksen, Marli, Taylor, Robert W., Patel, Krutik, Bisschoff, Michelle, Meldau, Surita, Vandrovcova, Jana, van der Watt, George, Fassad, Mahmoud R., Spencer, Careni, Naidu, Kireshnee, Henning, Franclo, McFarland, Robert, van der Westhuizen, Francois H.

2024

Overview

Background Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder resulting from pathogenic variants in three distinct genes, with most of the variants occurring in the electron transfer flavoprotein-ubiquinone oxidoreductase gene ( ETFDH) . Recent evidence of potential founder variants for MADD in the South African (SA) population, initiated this extensive investigation. As part of the International Centre for Genomic Medicine in Neuromuscular Diseases study, we recruited a cohort of patients diagnosed with MADD from academic medical centres across SA over a three-year period. The aim was to extensively profile the clinical, biochemical, and genomic characteristics of MADD in this understudied population. Methods Clinical evaluations and whole exome sequencing were conducted on each patient. Metabolic profiling was performed before and after treatment, where possible. The recessive inheritance and phase of the variants were established via segregation analyses using Sanger sequencing. Lastly, the haplotype and allele frequencies were determined for the two main variants in the four largest SA populations. Results Twelve unrelated families (ten of White SA and two of mixed ethnicity) with clinically heterogeneous presentations in 14 affected individuals were observed, and five pathogenic ETFDH variants were identified. Based on disease severity and treatment response, three distinct groups emerged. The most severe and fatal presentations were associated with the homozygous c.[1067G > A];c.[1067G > A] and compound heterozygous c.[976G > C];c.[1067G > A] genotypes, causing MADD types I and I/II, respectively. These, along with three less severe compound heterozygous genotypes (c.[1067G > A];c.[1448C > T], c.[740G > T];c.[1448C > T], and c.[287dupA*];c.[1448C > T]), resulting in MADD types II/III, presented before the age of five years, depending on the time and maintenance of intervention. By contrast, the homozygous c.[1448C > T];c.[1448C > T] genotype, which causes MADD type III, presented later in life. Except for the type I, I/II and II cases, urinary metabolic markers for MADD improved/normalised following treatment with riboflavin and L-carnitine. Furthermore, genetic analyses of the most frequent variants (c.[1067G > A] and c.[1448C > T]) revealed a shared haplotype in the region of ETFDH , with SA population-specific allele frequencies of < 0.00067–0.00084%. Conclusions This study reveals the first extensive genotype–phenotype profile of a MADD patient cohort from the diverse and understudied SA population. The pathogenic variants and associated variable phenotypes were characterised, which will enable early screening, genetic counselling, and patient-specific treatment of MADD in this population.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Acyl-CoA dehydrogenase deficiencies / Chemical properties / Child, Preschool / Death Domain Receptor Signaling Adaptor Proteins - genetics / Death Domain Receptor Signaling Adaptor Proteins - metabolism / Development and progression / Electron transport / ETFDH / Galactosemia / Genetic aspects / Genotype / Glutaric aciduria type II / Guanine Nucleotide Exchange Factors - genetics / Guanine Nucleotide Exchange Factors - metabolism / Guanine Nucleotide Exchange Factors - therapeutic use / Health aspects / Health counseling / Human Genetics / Humans / Levocarnitine / MADD / Medical centers / Medical genetics / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Multiple Acyl Coenzyme A Dehydrogenase Deficiency - diagnosis / Multiple Acyl Coenzyme A Dehydrogenase Deficiency - drug therapy / Multiple Acyl Coenzyme A Dehydrogenase Deficiency - genetics / Multiple acyl-CoA dehydrogenase deficiency / Mutation - genetics / Pharmacology/Toxicology / Physiological aspects / Riboflavin / Riboflavin - therapeutic use / South Africa